Docoh
Loading...

APTO Aptose Biosciences

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Company profile

Ticker
APTO
Exchange
Website
CEO
William Rice
Employees
Incorporated
Location
Fiscal year end
Former names
Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.), IMUTEC PHARMA INC, LORUS THERAPEUTICS INC
SEC CIK

APTO stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

23 Mar 21
17 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 117.39M 117.39M 117.39M 117.39M 117.39M 117.39M
Cash burn (monthly) (positive/no burn) (positive/no burn) 4.92M 4.65M 3.45M 2.82M
Cash used (since last report) n/a n/a 17.54M 16.57M 12.3M 10.07M
Cash remaining n/a n/a 99.85M 100.82M 105.09M 107.32M
Runway (months of cash) n/a n/a 20.3 21.7 30.5 38.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
4 Jan 21 Ashe Carol Gail Director Stock Option Common Shares Grant Aquire A No No 4.37 50,000 218.5K 50,000
4 Jan 21 Rafael Bejar Employee Stock Option Common Shares Grant Aquire A No No 4.37 343,000 1.5M 343,000
4 Jan 21 Burger Denis R Director Stock Option Common Shares Grant Aquire A No No 4.37 50,000 218.5K 50,000
4 Jan 21 Chow Gregory K. Employee Stock Option Common Shares Grant Aquire A No No 4.37 343,000 1.5M 343,000
4 Jan 21 Loewy Caroline M Director Stock Option Common Shares Grant Aquire A No No 4.37 50,000 218.5K 50,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Competition
Viracta Therapeutics
Management Discussion
  • Net loss of $55.2 million for the year ended December 31, 2020 increased by approximately $28.9 million as compared with $26.3 million for the year ended December 31, 2019, primarily as a result of an increase of $19.1 million in stock-based compensation in the current period, a combined increase in program costs and related labor costs of approximately $9.8 million on our luxeptinib development program and higher cash-based general and administrative expenses of approximately $549 thousand. These expenses were partially offset by lower costs of $545 thousand on our APTO-253 development programs.
  • R&D expenses increased by $12.5 million to $29.3 million for the year ended December 31, 2020 as compared with $16.8 million for the comparative period in 2019. Changes to the components of our R&D expenses presented in the table above are primarily as a result of the following activities:
  • General and administrative expenses for the year ended December 31, 2020 were approximately $26.5 million as compared with $10.0 million for the comparative period in 2019, an increase of approximately $16.5 million. The increase was primarily as a result of the following:
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg